For US residents only.

How Treatment May Help

AFINITOR Tablets and AFINITOR DISPERZ 

AFINITOR SHRINKS TSC-RELATED SEGA TUMORS AND MAY PREVENT NEW ONES FROM GROWING

In a long-term study, AFINITOR® (everolimus) reduced SEGA tumors, starting at 6 months and continuing for about 4 years. A total of 111 patients (78 patients received AFINITOR and 33 patients received placebo) participated in the study. The size of the SEGA tumor was measured every 6 months in patients taking AFINITOR. 

 

As early as 6 months, 35% of people had their tumor shrink to half its size  

58% of people had their sega tumor reduce by half

 

  • Average length of treatment was about 4 years (range: 0.2 to 4.9 years)

 No patient needed surgery for SEGA during the 4-year study

 

 

In another long-term study, AFINITOR reduced the size of SEGA tumors, starting at 6 months and continuing through 5 years. The size of SEGA tumors was measured every 6 months in people taking AFINITOR. 

 

As early as 6 months, 9 out of 28 people (32%) had their tumor shrink to half its size*  

At 5 years, 89% had no progression of their SEGA

*An additional 9 patients had a ≥50% reduction in their largest SEGA tumor between 1 to 4 years after initiating AFINITOR, including 3 patients who had regrowth of a tumor after surgery but before receiving AFINITOR. 
Progression is defined as a ≥25% increase in size of the largest tumor compared to its starting size. 

 

At 5 years, Over 80% of patients continued AFINITOR therapy

 

  • Average length of treatment was 5.7 years (range: 5 months to 6.9 years)  
  • No patient developed new SEGAs on AFINITOR therapy